Back to News
Market Impact: 0.3
Spyre Therapeutics Prices $350 Mln Public Offering Of Shares
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Spyre Therapeutics priced an offering of 4.11 million common shares at $85.00 per share, expected to generate approximately $350.0 million in gross proceeds. The report provides no details on the use of proceeds or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
SYRE0.35
More News
- GIC Private Ltd, Medline 10% owner, sells over $721m in shares
- A 32% beat, a +6% jump: the IT solutions name our models picked in July
- Nvidia Is on the Verge of a $6 Trillion Market Value
- Controversial $110 billion mega-merger of Paramount and Warner Bros. finally closes
- What Marvell's rosy long-term guidance means for our AI chip stocks
- Analysis-Vietnam’s banks tap investors for $7 billion as economy runs red hot
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Eli Lilly Q4 2025 Earnings: Revenue Surges 43% as Mounjaro and Zepbound Dominate the GLP-1 Market
- Investment Research Software Costs: A 2026 Budget Framework